Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

New on Charts:

We've added Splits, Dividends, Earnings, and Earnings Estimates! Click on individual events to unveil more details.

If you prefer a cleaner view, easily disable them in Settings.

SWTX | SpringWorks Therapeutics Inc

Index	RUT	P/E	-	EPS (ttm)	-4.98	Insider Own	22.95%	Shs Outstand	62.42M	Perf Week	-2.20%
Market Cap	1.45B	Forward P/E	-	EPS next Y	-4.44	Insider Trans	-0.03%	Shs Float	48.21M	Perf Month	-18.01%
Income	-297.91M	PEG	-	EPS next Q	-1.33	Inst Own	93.72%	Short Float / Ratio	30.24% / 28.07	Perf Quarter	-8.62%
Sales	0.00M	P/S	-	EPS this Y	-0.07%	Inst Trans	14.66%	Short Interest	14.58M	Perf Half Y	-6.05%
Book/sh	7.22	P/B	3.20	EPS next Y	14.84%	ROA	-67.46%	Target Price	58.67	Perf Year	-14.47%
Cash/sh	7.62	P/C	3.03	EPS next 5Y	-	ROE	-76.67%	52W Range	21.04 - 34.16	Perf YTD	-11.11%
Dividend	-	P/FCF	-	EPS past 5Y	-117.36%	ROI	-65.01%	52W High	-32.32%	Beta	0.64
Dividend %	-	Quick Ratio	11.55	Sales past 5Y	-20.00%	Gross Margin	-	52W Low	9.89%	ATR	1.31
Employees	227	Current Ratio	11.55	Sales Q/Q	-	Oper. Margin	0.00%	RSI (14)	35.83	Volatility	5.10% 4.74%
Optionable	Yes	Debt/Eq	0.02	EPS Q/Q	11.34%	Profit Margin	-	Rel Volume	1.04	Prev Close	24.17
Shortable	Yes	LT Debt/Eq	0.02	Earnings	Aug 02 BMO	Payout	-	Avg Volume	519.42K	Price	23.12
Recom	1.14	SMA20	-8.29%	SMA50	-14.29%	SMA200	-15.44%	Volume	540,791	Change	-4.34%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-01-22	Initiated	BofA Securities	Buy	$45
Jan-19-21	Reiterated	H.C. Wainwright	Buy	$87 → $101
Oct-29-20	Reiterated	H.C. Wainwright	Buy	$58 → $73
May-05-20	Initiated	Barclays	Overweight	$48
Mar-19-20	Upgrade	H.C. Wainwright	Neutral → Buy	$40 → $60
Mar-04-20	Downgrade	H.C. Wainwright	Buy → Neutral	$40
Jan-21-20	Reiterated	H.C. Wainwright	Buy	$34 → $40
Dec-04-19	Initiated	H.C. Wainwright	Buy
Oct-08-19	Initiated	Wedbush	Outperform	$33
Oct-08-19	Initiated	JP Morgan	Overweight	$32
Oct-08-19	Initiated	Goldman	Buy	$37
Oct-08-19	Initiated	Cowen	Outperform

Show Previous Ratings

Sep-11-23 06:30AM	SpringWorks Therapeutics Appoints Dr. Tai-An Lin as Chief Scientific Officer (GlobeNewswire)
Aug-02-23 06:30AM	SpringWorks Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights (GlobeNewswire) -6.87%
Jun-28-23 08:29PM	Goldman Sachs Says Attractive Valuations Make Small-Cap Stocks Appealing; Here Are 2 Strong Buy Names With Solid Upside Potential (TipRanks)
Jun-07-23 07:00AM	SpringWorks Therapeutics to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference (GlobeNewswire)
Jun-05-23 06:30AM	SpringWorks Therapeutics Announces PDUFA Date Extension for Nirogacestat NDA (GlobeNewswire)
06:30AM	Loading…
May-30-23 06:30AM	SpringWorks Therapeutics Announces Full Enrollment of Phase 2 Trial Evaluating Nirogacestat in Patients with Ovarian Granulosa Cell Tumors (GlobeNewswire)
May-25-23 05:05PM	SpringWorks Therapeutics Announces Presentation of Additional Data from Phase 3 DeFi Trial of Nirogacestat in Adults with Desmoid Tumors at the 2023 ASCO Annual Meeting (GlobeNewswire) -7.13%
May-24-23 07:00AM	SpringWorks Therapeutics to Participate in the TD Cowen 4th Annual Oncology Innovation Summit (GlobeNewswire)
May-11-23 12:14PM	SpringWorks Therapeutics Announces Clinical Data Presentations of Nirogacestat in Combination with BCMA-Directed Therapies at the European Hematology Association 2023 Congress (GlobeNewswire) +6.71%
May-03-23 06:30AM	SpringWorks Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights (GlobeNewswire)
May-02-23 07:00AM	SpringWorks Therapeutics to Participate in the Bank of America Securities 2023 Health Care Conference (GlobeNewswire)
Apr-17-23 02:32PM	SpringWorks and BeiGene Present Clinical Data on Lifirafenib, in combination with Mirdametinib, in Patients with Advanced or Refractory Solid Tumors with MAPK Pathway Aberrations at the American Association for Cancer Research Annual Meeting 2023 (GlobeNewswire)
02:30PM	MapKure, SpringWorks and BeiGene Present Clinical Data on BGB-3245, a Selective Next-Generation B-RAF Inhibitor, in Adult Patients with Advanced or Refractory Solid Tumors at the American Association for Cancer Research Annual Meeting 2023 (GlobeNewswire)
Mar-08-23 05:05PM	SpringWorks Therapeutics Announces New England Journal of Medicine Publication of Phase 3 DeFi Trial Evaluating Nirogacestat in Adults with Desmoid Tumors (GlobeNewswire)
Mar-01-23 07:00AM	SpringWorks Therapeutics to Participate in the Cowen 43rd Annual Health Care Conference (GlobeNewswire)
06:30AM	Loading…
Feb-28-23 06:30AM	SpringWorks Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Business Highlights (GlobeNewswire)
Feb-27-23 06:30AM	SpringWorks Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Nirogacestat for the Treatment of Adults with Desmoid Tumors (GlobeNewswire)
Jan-09-23 06:30AM	SpringWorks Therapeutics Highlights 2022 Accomplishments and Anticipated Milestones for 2023 at the 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-03-23 07:00AM	SpringWorks Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-27-22 06:30AM	SpringWorks Therapeutics Completes Submission of New Drug Application to the FDA for Nirogacestat for the Treatment of Adults with Desmoid Tumors (GlobeNewswire)
Nov-22-22 07:00AM	SpringWorks Therapeutics to Participate in the Evercore ISI 5th Annual HealthCONx Conference (GlobeNewswire)
Nov-03-22 06:30AM	SpringWorks Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights (GlobeNewswire)
Nov-01-22 11:07AM	Applied BioMath, LLC Announces Collaboration with SpringWorks Therapeutics, Inc. for Systems Pharmacology Modeling in Multiple Myeloma (PR Newswire)
Sep-29-22 06:30AM	SpringWorks Therapeutics Announces Dosing of First Patient in Phase 2 Trial Evaluating Nirogacestat in Patients with Ovarian Granulosa Cell Tumors (GlobeNewswire)
Sep-10-22 10:30AM	SpringWorks Therapeutics Announces Data from Phase 3 DeFi Trial Evaluating Nirogacestat in Adult Patients with Progressing Desmoid Tumors at the European Society for Medical Oncology (ESMO) Congress 2022 (GlobeNewswire)
Sep-07-22 09:56AM	SpringWorks Therapeutics Announces $225 Million Private Placement Financing (GlobeNewswire) +7.15%
09:55AM	SpringWorks Announces Expansion of Global, Non-Exclusive Collaboration with GSK for Nirogacestat in Combination with Blenrep in Patients with Multiple Myeloma (GlobeNewswire)
Aug-19-22 06:30AM	SpringWorks Therapeutics Announces Late-Breaking Oral Presentation of Phase 3 DeFi Data at the European Society for Medical Oncology (ESMO) Congress 2022 (GlobeNewswire) -8.63%
Aug-04-22 06:30AM	SpringWorks Therapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights (GlobeNewswire) +10.79%
Aug-02-22 07:00AM	SpringWorks Therapeutics to Present at the 2022 Wedbush PacGrow Healthcare Conference (GlobeNewswire)
06:30AM	Loading…
Jul-15-22 06:30AM	SpringWorks Therapeutics Appoints Carlos Albán to its Board of Directors (GlobeNewswire)
Jul-06-22 11:38AM	HC Wainwright Believes Ayala's Initial Cancer Data Is Encouraging (Benzinga)
Jun-13-22 09:04AM	SpringWorks Therapeutics Shares Jump On HC Wainwright Bullish Pitch (Benzinga) -8.28%
Jun-10-22 06:30AM	SpringWorks Therapeutics to Present Progress Across the Companys Targeted Oncology Portfolio at Virtual R&D Day (GlobeNewswire) -9.93%
Jun-09-22 07:00AM	SpringWorks Therapeutics to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference (GlobeNewswire) -6.65%
May-27-22 09:57AM	Biotech stocks get a boost, or plunge, as new clinical data is shared before major cancer meeting (MarketWatch) -40.45%
May-26-22 05:15PM	SpringWorks Therapeutics Highlights Nirogacestat Clinical Data at the 2022 ASCO Annual Meeting (GlobeNewswire) -5.63%
May-25-22 12:05PM	SpringWorks (SWTX) Down Despite Desmoid Tumors Study Meeting Goal (Zacks)
May-24-22 08:29AM	Why SpringWorks Shares Are Soaring Today Premarket (Benzinga) -11.37%
07:59AM	Is SpringWorks Therapeutics (NASDAQ:SWTX) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
07:39AM	SpringWorks shares jump 14%; company plans to seek FDA approval for desmoid tumor therapy this year (MarketWatch)
06:30AM	SpringWorks Therapeutics Announces Nirogacestat Achieved Primary and All Key Secondary Endpoints in Phase 3 DeFi Trial in Adult Patients with Progressing Desmoid Tumors (GlobeNewswire)
May-23-22 11:24AM	J.P. Morgan Says Buy These 3 Beaten-Down Stocks for Over 90% Upside Potential (TipRanks)
May-16-22 08:30AM	SpringWorks Therapeutics to Host Virtual R&D Day on June 10, 2022 (GlobeNewswire)
May-05-22 06:30AM	SpringWorks Therapeutics Reports First Quarter 2022 Financial Results and Recent Business Highlights (GlobeNewswire) -8.39%
Apr-19-22 06:30AM	SpringWorks Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Regeneron to Evaluate Nirogacestat in Combination with REGN5458 in Patients with Relapsed or Refractory Multiple Myeloma (GlobeNewswire)
Mar-18-22 09:15AM	Allogene (ALLO) Focuses on Pipeline Amid Lack of Marketed Drugs (Zacks)
Feb-24-22 06:30AM	SpringWorks Therapeutics Reports Fourth Quarter and Full-Year 2021 Financial Results and Recent Business Highlights (GlobeNewswire) +9.48%
Feb-15-22 05:03PM	8 Medical Stocks to Buy According to Mitchell Blutts Consonance Capital (Insider Monkey) +5.70%
Feb-08-22 01:38PM	CIBC Asset Management Inc Buys Bank of Nova Scotia, Franco-Nevada Corp, Suncor Energy Inc, ... (GuruFocus.com)
Feb-01-22 06:30AM	SpringWorks Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Jan-12-22 01:21PM	SpringWorks Therapeutics, Inc. (SWTX): Hedge Funds Are Snapping Up (Insider Monkey) +8.72%
Jan-04-22 06:30AM	SpringWorks Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -5.85%
Dec-27-21 09:38PM	Fiera Capital Small Mid-cap Growth Fund Buys Devon Energy Corp, Ares Management Corp, Icon ... (GuruFocus.com) -8.28%
Dec-17-21 05:38PM	Fiera Capital Corp Buys Devon Energy Corp, Gartner Inc, Ares Management Corp, Sells Rogers ... (GuruFocus.com)
Dec-15-21 08:53AM	We're Interested To See How SpringWorks Therapeutics (NASDAQ:SWTX) Uses Its Cash Hoard To Grow (Simply Wall St.)
Dec-13-21 02:24PM	Exicure Stock Plunges After Results Of Internal Probe, Management Shakeup, Layoffs (Benzinga)
11:56AM	SpringWorks (SWTX) & AbbVie Unite for Multiple Myeloma Drug (Zacks)
Dec-10-21 09:24AM	AbbVie, SpringWorks Join Forces To Conduct Multiple Myeloma Combo Therapy Trial (Benzinga)
06:30AM	SpringWorks Therapeutics Announces Clinical Collaboration with AbbVie to Evaluate Nirogacestat in Combination with ABBV-383 in Patients with Relapsed or Refractory Multiple Myeloma (GlobeNewswire)
Dec-06-21 06:30AM	SpringWorks Therapeutics Announces Dosing of First Patient in Phase 1b/2 Trial Evaluating Nirogacestat in Combination with Elranatamab (PF-06863135) in Patients with Relapsed or Refractory Multiple Myeloma (GlobeNewswire) -5.30%
Nov-29-21 06:30AM	SpringWorks Therapeutics Announces Full Enrollment of Phase 2b ReNeu Trial Evaluating Mirdametinib in Adult and Pediatric Patients with NF1-Associated Plexiform Neurofibromas (GlobeNewswire)
Nov-23-21 06:30AM	SpringWorks Therapeutics to Participate in the 4th Annual Evercore ISI HealthCONx Conference (GlobeNewswire)
Nov-10-21 09:35AM	Were These Hedge Funds Right About Dumping SpringWorks Therapeutics, Inc. (SWTX)? (Insider Monkey)
Nov-04-21 06:30AM	SpringWorks Therapeutics Reports Third Quarter 2021 Financial Results and Recent Business Highlights (GlobeNewswire)
Oct-27-21 06:30AM	SpringWorks Therapeutics Announces the Initiation of an Expanded Phase 2 Cohort and Addition of New Sub-Studies to Existing Clinical Collaboration with GlaxoSmithKline Evaluating Nirogacestat in Combination with BLENREP in Patients with Relapsed or Refractory Multiple Myeloma (GlobeNewswire) +7.43%
Oct-20-21 06:45AM	SpringWorks Therapeutics to Collaborate with Ab Magnitude on Target Identification and Discovery of Next-Generation Targeted Oncology Therapeutics (GlobeNewswire)
06:30AM	SpringWorks Therapeutics to Collaborate with Leading Academic Institutions to Advance Portfolio of Next-Generation Mutation-Selective EGFR Inhibitors (GlobeNewswire)
Sep-29-21 08:47AM	15 Biotech Stocks to Buy Now According to Srini Akkaraju and Michael Dybbs Samsara BioCapital (Insider Monkey)
Sep-07-21 12:16PM	While shareholders of SpringWorks Therapeutics (NASDAQ:SWTX) are in the black over 1 year, those who bought a week ago aren't so fortunate (Simply Wall St.)
06:30AM	SpringWorks Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference (GlobeNewswire)
Aug-30-21 06:30AM	SpringWorks Therapeutics Enters into Research Collaboration with Leading Cancer Institute to Further Evaluate Nirogacestat as a BCMA Potentiator in Multiple Myeloma (GlobeNewswire)
Aug-13-21 10:24AM	New Strong Sell Stocks for August 13th (Zacks)
Aug-04-21 06:30AM	SpringWorks Therapeutics Reports Second Quarter 2021 Financial Results and Recent Business Highlights (GlobeNewswire)
Aug-03-21 09:00AM	SpringWorks Therapeutics to Present at the 12th Annual Wedbush PacGrow Healthcare Conference (GlobeNewswire)
06:30AM	SpringWorks Therapeutics Announces Phase 1b/2a Clinical Trial of Mirdametinib in Patients with Advanced Solid Cancers Harboring MAPK-Activating Mutations (GlobeNewswire)
Jul-27-21 08:00AM	SpringWorks Therapeutics Appoints Dr. James Cassidy as Chief Medical Officer (GlobeNewswire)
Jul-20-21 07:30AM	SpringWorks Therapeutics Announces Issuance of New U.S. Composition of Matter Patent to Polymorphic Form of Mirdametinib, Extending Patent Protection Into 2041 (GlobeNewswire) +7.68%
Jul-19-21 12:08PM	Where Do Hedge Funds Stand On SpringWorks Therapeutics, Inc. (SWTX)? (Insider Monkey)
Jun-29-21 08:46AM	Precision BioSciences (DTIL) Surges 6.6%: Is This an Indication of Further Gains? (Zacks)
Jun-28-21 07:00AM	Precision BioSciences and SpringWorks Therapeutics Dose First Patient in Expanded Phase 1/2a Clinical Trial Evaluating PBCAR269A with Nirogacestat in Patients with Relapsed/Refractory Multiple Myeloma (Business Wire)
Jun-19-21 07:00AM	A Biotech Pro Exited Novavax Stock. Here Are Three Stocks It Bought. (Barrons.com)
Jun-16-21 06:40AM	SpringWorks Therapeutics Reveals Updated Interim Mirdametinib Data In Rare Genetic Disorder (Benzinga)
06:30AM	SpringWorks Therapeutics Announces Initiation of Phase 1/2 Clinical Trial of Mirdametinib in Children and Young Adults with Low-Grade Glioma (GlobeNewswire)
Jun-15-21 04:05PM	SpringWorks Therapeutics Announces Presentation of Updated Interim Data from the Phase 2b ReNeu Trial at the 2021 Childrens Tumor Foundation NF Conference (GlobeNewswire)
Jun-10-21 09:04AM	New Strong Sell Stocks for June 10th (Zacks)
Jun-08-21 07:08AM	We Think SpringWorks Therapeutics (NASDAQ:SWTX) Can Easily Afford To Drive Business Growth (Simply Wall St.)
Jun-07-21 06:30AM	SpringWorks Therapeutics Announces Clinical Collaboration with Seagen to Evaluate Nirogacestat in Combination with SEA-BCMA in Patients with Relapsed or Refractory Multiple Myeloma (GlobeNewswire) +7.56%
Jun-01-21 06:30AM	SpringWorks Therapeutics to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference (GlobeNewswire)
May-14-21 06:30AM	SpringWorks Therapeutics to Present at the Cowen 2nd Annual Oncology Innovation Summit (GlobeNewswire) +7.00%
May-10-21 06:30AM	SpringWorks Therapeutics Appoints Dr. Mike Burgess as Head of Research and Development (GlobeNewswire) -6.43%
May-06-21 06:30AM	SpringWorks Therapeutics Reports First Quarter 2021 Financial Results and Recent Business Highlights (GlobeNewswire)
06:04AM	SpringWorks Therapeutics Expands Targeted Oncology Pipeline with Exclusive Worldwide License to TEAD Inhibitor Portfolio (GlobeNewswire)
Apr-12-21 08:30AM	Allogene Therapeutics and SpringWorks Therapeutics Announce Dosing of First Patient in Phase 1 Study Evaluating ALLO-715 in Combination with Nirogacestat in Patients with Relapsed or Refractory Multiple Myeloma (GlobeNewswire)
Apr-05-21 08:18AM	SpringWorks (SWTX) Begins Dosing in Multiple Myeloma Study (Zacks)
Apr-01-21 09:17AM	SpringWorks Therapeutics Stock Is Trading Higher After Nirogacestat Combo Study Starts Dosing In Multiple Myeloma Patients (Benzinga)
06:30AM	SpringWorks Therapeutics Announces Dosing of First Patient in Phase 1b Combination Study Evaluating Nirogacestat and Janssens BCMA Bispecific Antibody Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma (GlobeNewswire)
Mar-28-21 12:44PM	Goldman Sachs Bets on These 3 Stocks; Sees Over 50% Upside Potential (TipRanks)
Mar-22-21 06:30AM	SpringWorks Therapeutics Appoints Bhavesh Ashar as Chief Commercial Officer (GlobeNewswire)
Mar-12-21 06:07PM	AnaptysBio and Seagate Technology See Activist Action (Barrons.com)

Springworks Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the application of a medicine approach to acquiring, developing, and commercializing medicines. Its pipeline includes Nirogacestat, Mirdametinib, BGB-3245 (RAF Fusion and Dimer Inhibitor), SW-682 (TEAD Inhibitor), and EGFR Inhibitor. The company was founded in August 2017 and is headquartered in Stamford, CT.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Hambleton Julie	Director	Jul 19	Sale	29.31	2,418	70,876	4,648	Jul 21 04:13 PM
Hambleton Julie	Director	Jun 20	Sale	26.92	2,400	64,603	7,066	Jun 22 04:06 PM
Schwartz Jeffrey Lawrence	Director	Mar 16	Sale	28.50	1,750,000	49,875,000	3,081,307	Mar 20 05:00 PM
Hambleton Julie	Director	Mar 15	Sale	31.50	1,106	34,841	4,818	Mar 16 04:31 PM
Pichl Daniel	Chief People Officer	Jan 26	Sale	31.00	858	26,598	35,203	Jan 27 04:30 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SWTX | SpringWorks Therapeutics Inc

Upgrade your FINVIZ experience